Liverpool Women's NHS Foundation Trust

CQC Registered Health or/and Social Care provider

Nimish Subhedar

Liverpool Women's NHS Foundation Trust

No

NNRD0041

The iNO (Inhaled nitric oxide) study’s Chief Investigator is Nimish Subhedar, Neonatologist, Liverpool Women’s Hospital. Dr Chris Gale, Senior Lecturer, Imperial College, London and Eugene Statnikov, Senior Data Manager, Neonatal Data Analysis Unit, Imperial College, London are Co-investigators. Inhaled nitric oxide (iNO) is widely used in the treatment of hypoxaemic respiratory failure and persistent pulmonary hypertension of the newborn. Although a well-established therapy in term and near-term infants, its use in preterm infants < 34 weeks’ gestation remains controversial. Population based data indicates that there is wide variation in administration rates amongst US hospitals, but there is no equivalent data from the UK or mainland Europe [1-4]. Data from individual centres and multicentre studies suggests that the use of iNO is increasing in recent years, especially in preterm infants, despite the lack of a clear evidence base in this population. The iNO study aims to describe hospital variation in patient demographics and treatment rates relating to the use of inhaled nitric oxide in term and preterm infants admitted to neonatal units in England.

REC reference: 16/WS/0228

02/11/2016

Release

Removal of personal identifiers; replacement of dates with 'minutes from birth'